Trial Profile

A Phase 1b, Single and Multiple Dose, Open-Label Trial of Intravenous GMI-1359 in HR+ Metastatic Breast Cancer Subjects

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 23 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GMI 1359 (Primary)
Indications Advanced breast cancer
Focus Adverse reactions; Proof of concept
Sponsors GlycoMimetics

Most Recent Events

07 Mar 2022 Status changed from recruiting to discontinued.
10 Apr 2021 Results (n=2) assessing safety and effects of GMI-1359 on tumor-microenvironment, presented at the 112th Annual Meeting of the American Association for Cancer Research
10 Apr 2021 Results published in the GlycoMimetics media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com